GlassScriptPhysician profile
Sujal Singh
NPI 1609302314
$3,472.62
in general payments reported to CMS, 2019-2025
29 companies · $546 in 2025
The $546 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $585 · 2022: $1,051 · 2023: $775 · 2024: $516 · 2025: $546.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,837.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,836.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $584.60 | 2021-2025 | Vraylar, Linzess, Viberzi |
| Lilly USA, LLC | $554.62 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $487.73 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $325.74 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Dexcom, INC. | $309.65 | 2022-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $180.36 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Daiichi Sankyo INC. | $177.86 | 2021-2023 | Injectafer |
| Merck Sharp & Dohme LLC | $147.85 | 2021-2023 | Verquvo, Steglatro, Belsomra |
| Glaxosmithkline, LLC. | $99.87 | 2022-2025 | Shingrix, Arexvy, Bexsero |
| Scilex Pharmaceuticals INC. | $73.16 | 2022-2025 | Ztlido |
| Sanofi-Aventis U.S. LLC | $54.25 | 2021-2025 | |
| Phathom Pharmaceuticals, INC. | $50.60 | 2024-2025 | Voquezna |
| Corcept Therapeutics | $47.60 | 2021-2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.93 | 2021-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $38.84 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $37.21 | 2024 | Rexulti |
| Pfizer INC. | $35.69 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.14 | 2024 | Xifaxan |
| Exact Sciences Corporation | $30.48 | 2025 | The Cologuard Plus Collection Kit |
| Arbor Pharmaceuticals, INC. | $27.72 | 2021 | |
| Neurocrine Biosciences, INC. | $17.00 | 2023 | Ingrezza |
| Nevro Corp. | $16.34 | 2023 | Senza |
| Optinose US, INC. | $14.36 | 2021 | |
| Genentech USA, INC. | $14.29 | 2021 | |
| Nestle Healthcare Nutrition INC. | $14.21 | 2021 | |
| Xeris Pharmaceuticals, INC. | $13.61 | 2023 | Gvoke Hypopen |
| Amarin Pharma, INC. | $13.38 | 2021 | |
| Amgen INC. | $12.76 | 2022 | |
| Bausch Health US, LLC | $11.77 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sujal Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.